ID

43879

Descripción

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT00515138

Link

https://clinicaltrials.gov/show/NCT00515138

Palabras clave

Versiones (2)
  1. 29/6/17 29/6/17 -
  2. 20/9/21 20/9/21 -
Subido en

20 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Lymphoma, B-Cell NCT00515138

Inglés

Eligibility Lymphoma, B-Cell NCT00515138

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
aggressive b-cell lymphoma, cd-20 positive, in first relapse or refractory to first-line chemotherapy
Descripción

ID.1

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0855090
UMLS CUI [1,2]
C3888518
UMLS CUI [1,3]
C0392920
diffuse large b-cell lymphoma, mantle cell lymphoma, follicular lymphoma (grade iii), transformed follicular lymphoma
Descripción

ID.2

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0079744
UMLS CUI [1,2]
C0677725
UMLS CUI [1,3]
C0024301
rituximab is allowed
Descripción

ID.3

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0393022
prior radiation is allowed
Descripción

ID.4

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1522449
18-70 years of age
Descripción

ID.5

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
ecog performance status of 0-2
Descripción

ID.6

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3541269
hiv seronegative
Descripción

ID.7

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019698
measurable disease on ct scan by international working group response criteria
Descripción

ID.8

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0040405
no cns involvement
Descripción

ID.9

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3714787
subject is considered to be a candidate for autologous stem cell transplant in the opinion of the treating physician
Descripción

ID.10

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2193200
female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control
Descripción

ID.11

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009862
UMLS CUI [1,2]
C0232970
male subject agrees to use an acceptable method of contraception for the duration of the study
Descripción

ID.12

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009862
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
platelet count of <75 x 10(9)/l
Descripción

ID.13

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032181
absolute neutrophil count of <1.0 x 10(9)/l
Descripción

ID.14

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0151683
calculated or measured creatinine clearance of <60 ml/minute within 14 days before enrollment
Descripción

ID.15

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0373595
myocardial infarction within 6 months prior to enrollment or has new york hospital association class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. prior to study entry, any ecg abnormality at screening has to be documented by the investigator as not medically relevant.
Descripción

ID.16

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018799
subject has hypersensitivity to bortezomib, boron or mannitol.
Descripción

ID.17

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1176309
UMLS CUI [1,2]
C0006030
UMLS CUI [1,3]
C0024730
UMLS CUI [1,4]
C0020517
female subject is pregnant or breast-feeding.
Descripción

ID.18

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
subject has been treated with more than one prior chemotherapy regimen.
Descripción

ID.19

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
subject has received other investigational drugs with 14 days before enrollment.
Descripción

ID.20

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013230
serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Descripción

ID.21

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0012634
Volver a la parte superior de la página

Similar models

Eligibility Lymphoma, B-Cell NCT00515138

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
aggressive b-cell lymphoma, cd-20 positive, in first relapse or refractory to first-line chemotherapy
boolean
C0855090 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
ID.2
Item
diffuse large b-cell lymphoma, mantle cell lymphoma, follicular lymphoma (grade iii), transformed follicular lymphoma
boolean
C0079744 (UMLS CUI [1,1])
C0677725 (UMLS CUI [1,2])
C0024301 (UMLS CUI [1,3])
ID.3
Item
rituximab is allowed
boolean
C0393022 (UMLS CUI [1])
ID.4
Item
prior radiation is allowed
boolean
C1522449 (UMLS CUI [1])
ID.5
Item
18-70 years of age
boolean
C0001779 (UMLS CUI [1])
ID.6
Item
ecog performance status of 0-2
boolean
C3541269 (UMLS CUI [1])
ID.7
Item
hiv seronegative
boolean
C0019698 (UMLS CUI [1])
ID.8
Item
measurable disease on ct scan by international working group response criteria
boolean
C0040405 (UMLS CUI [1])
ID.9
Item
no cns involvement
boolean
C3714787 (UMLS CUI [1])
ID.10
Item
subject is considered to be a candidate for autologous stem cell transplant in the opinion of the treating physician
boolean
C2193200 (UMLS CUI [1])
ID.11
Item
female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control
boolean
C0009862 (UMLS CUI [1,1])
C0232970 (UMLS CUI [1,2])
ID.12
Item
male subject agrees to use an acceptable method of contraception for the duration of the study
boolean
C0009862 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
ID.13
Item
platelet count of <75 x 10(9)/l
boolean
C0032181 (UMLS CUI [1])
ID.14
Item
absolute neutrophil count of <1.0 x 10(9)/l
boolean
C0151683 (UMLS CUI [1])
ID.15
Item
calculated or measured creatinine clearance of <60 ml/minute within 14 days before enrollment
boolean
C0373595 (UMLS CUI [1])
ID.16
Item
myocardial infarction within 6 months prior to enrollment or has new york hospital association class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. prior to study entry, any ecg abnormality at screening has to be documented by the investigator as not medically relevant.
boolean
C0018799 (UMLS CUI [1])
ID.17
Item
subject has hypersensitivity to bortezomib, boron or mannitol.
boolean
C1176309 (UMLS CUI [1,1])
C0006030 (UMLS CUI [1,2])
C0024730 (UMLS CUI [1,3])
C0020517 (UMLS CUI [1,4])
ID.18
Item
female subject is pregnant or breast-feeding.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
ID.19
Item
subject has been treated with more than one prior chemotherapy regimen.
boolean
C0392920 (UMLS CUI [1])
ID.20
Item
subject has received other investigational drugs with 14 days before enrollment.
boolean
C0013230 (UMLS CUI [1])
ID.21
Item
serious medical or psychiatric illness likely to interfere with participation in this clinical study.
boolean
C0004936 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial